In the world of healthcare investing, the ASX 200 Healthcare Index has been on a downward spiral, with a 40% decline over the past year. This sector, which has been facing a myriad of challenges, from currency headwinds to the potential impact of artificial intelligence, has left investors wary and wondering where to put their money. But, amidst the gloom, there are some healthcare shares that have attracted new buy ratings, offering a glimmer of hope for those looking to capitalize on the sector's struggles. In this article, I'll be taking a closer look at four ASX healthcare shares that have been making waves, despite the sector's overall downturn. From medical imaging software to cellular medicines and sleep devices, these companies are offering innovative solutions that could shape the future of healthcare. But, before we dive into the details, let's take a step back and consider the broader implications of the healthcare sector's struggles. The challenges facing the sector are multifaceted, and they are likely to persist for some time. However, amidst the uncertainty, there are opportunities to be found, and these four healthcare shares are prime examples of how investors can capitalize on the sector's struggles. So, without further ado, let's take a closer look at each of these companies and explore why they have caught the eye of investors, despite the sector's overall downturn. Personally, I think that the healthcare sector's struggles are a testament to the challenges facing the industry as a whole. However, amidst the uncertainty, there are opportunities to be found, and these four healthcare shares are prime examples of how investors can capitalize on the sector's struggles. Pro Medicus Ltd (ASX: PME) is a medical imaging software and services company that has been on a downward spiral in recent months. The company's share price has fallen 46% over six months, and it hit a record high of $336 per share just last July. However, despite the recent decline, Morgan Stanley maintains a buy rating with a 12-month target of $200, implying a 45% upside ahead. What makes this particularly fascinating is the potential for Pro Medicus to capitalize on the growing demand for medical imaging software and services, particularly in the developing world. In my opinion, Pro Medicus is well-positioned to benefit from the increasing adoption of medical imaging technology, and its innovative solutions could help to drive growth in the sector. Mesoblast Ltd (ASX: MSB) is a biopharmaceutical company that specializes in allogeneic cellular medicines for severe inflammatory diseases. The company's share price has fallen 20% in the year to date, but Bell Potter has reaffirmed its speculative buy rating, with a $4.45 price target on Mesoblast shares, suggesting a doubling in value over the next year. What makes this particularly interesting is the potential for Mesoblast to capitalize on the growing demand for cellular medicines, particularly in the treatment of inflammatory diseases. From my perspective, Mesoblast is well-positioned to benefit from the increasing focus on cellular medicine, and its innovative solutions could help to drive growth in the sector. Resmed CDI (ASX: RMD) is a sleep device developer that has been making waves in the healthcare sector. The company's share price has fallen 18.5% in the year to date, but Morgans has reiterated its buy rating after the company released its 3Q FY26 report. What makes this particularly noteworthy is the potential for Resmed to capitalize on the growing demand for sleep devices, particularly in the treatment of sleep apnea and other sleep disorders. In my view, Resmed is well-positioned to benefit from the increasing awareness of sleep disorders and the growing demand for effective treatments. Cochlear Ltd (ASX: COH) is a hearing implant maker that has been facing a number of challenges, including capacity constraints at hospitals, falling consumer confidence, and cancellations in the Middle East. However, Canaccord Genuity sees an opportunity, and reiterated its buy rating on the company last week. What makes this particularly intriguing is the potential for Cochlear to capitalize on the growing demand for hearing implants, particularly in the developing world. From my perspective, Cochlear is well-positioned to benefit from the increasing awareness of hearing loss and the growing demand for effective treatments. In conclusion, the healthcare sector may be struggling, but amidst the uncertainty, there are opportunities to be found. These four ASX healthcare shares are prime examples of how investors can capitalize on the sector's struggles, and they offer a glimmer of hope for those looking to invest in the sector. However, it's important to remember that investing in healthcare shares is not without risk, and investors should carefully consider their options before making any decisions. Personally, I think that the healthcare sector's struggles are a testament to the challenges facing the industry as a whole, but amidst the uncertainty, there are opportunities to be found. These four healthcare shares are prime examples of how investors can capitalize on the sector's struggles, and they offer a glimmer of hope for those looking to invest in the sector. But, as always, investors should carefully consider their options before making any decisions.
